Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies
- 1 February 2018
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (2), 286-292
- https://doi.org/10.2337/dc17-0280
Abstract
OBJECTIVE Concerns have been raised about a possible increased risk of pancreatic cancer associated with incretin-based therapies. We examined the risk of pancreatic cancer among patients with diabetes prescribed incretin drugs. RESEARCH DESIGN AND METHODS With the use of public health insurance databases of Belgium and the Lombardy Region, Italy, we created two retrospective cohorts that included adult patients who were first prescribed an incretin drug or another noninsulin antidiabetic drug (NIAD) from 1 July 2008 to 31 December 2013 in Belgium and from 1 January 2008 to 31 December 2012 in the Lombardy Region. The risk of pancreatic cancer was evaluated by multivariate-adjusted Cox models that included time-dependent variables. Adjusted hazard ratios (aHRs) from Belgium and Italy were pooled by using fixed-effects meta-analyses. RESULTS The cohorts included 525,733 patients with diabetes treated with NIADs and 33,292 with incretin drugs. Results in both cohorts were similar. Eighty-five and 1,589 subjects who developed pancreatic cancer were registered among the incretin and NIAD new users, respectively, which represented an aHR of pancreatic cancer of 2.14 (95% CI 1.71-2.67) among those prescribed an incretin compared with an NIAD. The aHR with a drug use lag exposure of 6 months was 1.69 (1.24-2.32). The aHR decreased from 3.35 (2.32-4.84) in the first 3 months after the first incretin prescription to 2.12 (1.22-3.66) in months 3-5.9, 1.95 (1.20-3.16) in months 6-11.9, and 1.69 (1.12-2.55) after 12 months. Among those prescribed an NIAD, pancreatic cancer occurred mostly within the year after the first prescription. The risk of pancreatic cancer among patients subsequently prescribed insulin was 6.89 (6.05-7.85). CONCLUSIONS The recent prescription of incretin therapy is associated with an increased risk of pancreatic cancer. The reason for such an increase is likely the consequence of an occult pancreatic cancer that provokes or aggravates diabetes. Studies are warranted for assessing the risk of pancreatic cancer associated with long-term use of incretin drugs.Funding Information
- Sanofi
This publication has 34 references indexed in Scilit:
- A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondDrugs in Context, 2015
- Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Expert Opinion on Drug Safety, 2014
- A prospective, claims‐based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugsDiabetes, Obesity and Metabolism, 2013
- A Critical Analysis of the Clinical Use of Incretin-Based TherapiesDiabetes Care, 2013
- Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?JAMA Internal Medicine, 2013
- Incretin-based therapies in the treatment of type 2 diabetes — More than meets the eye?European Journal of Internal Medicine, 2013
- GLP-1 based agents and acute pancreatitisBMJ, 2013
- GLP1 and cancer: friend or foe?Endocrine-Related Cancer, 2012
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- GLP-1–Based Therapies: The Dilemma of UncertaintyGastroenterology, 2011